Skip to main content
Signal8

ANAPTYSBIO, INC Form SCHEDULE 13D/A — Nov 18, 2026

Form SCHEDULE 13D/AFiled Nov 18, 2026, 7:03 PM ET0000935836-26-000634Original filing

EcoR1 Capital, LLC and manager Oleg Nodelman filed Amendment No. 4 to their Schedule 13D on AnaptysBio, disclosing beneficial ownership of 8,254,674 shares, or 27.8% of the common stock. The filing shows continued buying: roughly 374,580 shares purchased in the open market between November 16 and November 18, 2026 at prices around $45.66 to $46.54 per share, bringing the funds' cumulative investment to about $154.7 million. Nodelman serves on AnaptysBio's board, and while the reporting persons state they have no present plan or proposal, they explicitly reserve the right to recommend strategic actions, including potential mergers, asset sales, or changes in control.

Key figures

Shares Outstanding
0
Percent of class
27.8%
Qualified fund shares
7642937
Aggregate shares owned
8254674
Qualified fund percent
25.7%

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.